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Recently, insulin has been used as a pro-cognitive agent for the potential treatment of Alzheimer’s disease (AD),
because of its ability to cross the brain–blood barrier (BBB) by a saturable transport system. This study has been
designed to evaluate the effects of intranasal insulin regimen, as a bypass system of BBB, on spatial memory in
amyloid-beta (Aβ) model of AD in rat. Unilateral infusion of Aβ25–35 (10 nmol/2 μl/rat) into the lateral
ventricular region of brain was used to produce a rat model of AD. After a 24-h recovery period, rats received
insulin or vehicle via intraperitoneal or intranasal route (0.1, 0.2, and 0.3 IU) for 14 days. Memory function in
rats was assessed by Morris water maze test, with 5 days of training and consequent probe test protocol.
Different doses of intraperitoneal insulin did not have a signiﬁcant effect on learning and memory in AD rats.
However, intranasal insulin at doses of 0.2 and 0.3 IU improved the learning and memory in Aβ-received rats.
In conclusion, intranasal insulin as a non-invasive strategy improves spatial learning and memory in
AD model.
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Introduction
Alzheimer’s disease (AD) is the most common neurodegenerative disorder that affects aged
population (41). According to the 2010 World Alzheimer’s Report, more than 36 million
people are living with dementia, and it is expected that this number will be tripled by 2050
(40, 48). Cognitive decline, a major symptom exhibited by patients with AD, is associated
with amyloid-beta (Aβ) deposition in the brain tissue (42, 43).
In general, AD is a metabolic disease in which brain glucose utilization and energy
production are impaired (16). This disease exhibits metabolic abnormalities, such as
glucose metabolism impairment, abnormal insulin receptor signaling, insulin resistance,
oxidative stress, and structural abnormalities in proteins (18). Moreover, dementia in
sporadic AD type is associated with dysfunction of the insulin receptor followed by
decreased glucose transport via glucose transporter 4 (GLUT-4) and decreased glucose
metabolism in brain cells (45).
Evidence shows that insulin dysregulation could contribute to the expression of late-life
neurodegenerative disorders (13). On the other hand, anti-diabetic drugs have showed
beneﬁcial effects on glycolysis and other metabolic alterations during AD (18).
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Recently, insulin has received much attention for its potential, beneﬁcial, and protective
roles in cognitive function (10). Although long-term insulin therapy may lead to severe
hypoglycemia (14) and this risk increases with diabetes (23).
Because of the existence of brain–blood barrier (BBB) in cerebral vasculature, systemic
delivery of therapeutics from the circulating blood to the central nervous system (CNS) is not
effective for more than 98% of small molecules and nearly 100% of large molecules (17).
Therapeutics can be directly introduced into the CNS by intracerebroventricular (i.c.v.)
or intraparenchymal injections; however, for multiple dose regimens, both the delivery
methods are invasive, risky, and expensive techniques requiring surgical expertise (32).
Intranasal delivery of insulin, which was ﬁrst introduced by W. H. Frey (55), is a non-
invasive and rapid brain delivery method, which bypasses the BBB and delivers insulin to the
CNS through olfactory and trigeminal nerves (17, 37). This method has been successfully
used in animal studies and clinical trials (11, 20, 39).
Materials and Methods
Experimental design
Wistar rats (weighing 250–270 g), which were purchased from Laboratory Animal
Care Center of Tabriz University of Medical Sciences (TUOMS), were housed in a
temperature-controlled environment with an alternating 12-h light/dark cycle for
at least 7 days prior to treatment and were fed standard laboratory chow (Pars Khoram
dam, Iran). The room temperature was maintained at 22 ± 2 °C. All stressful conditions
were avoided. The experimental procedures were carried out in accordance with the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health
(NIH; Publication No. 85-23, revised 1985) and in compliance with the animal care and
use committee guidelines of TUOMS.
Aβ preparation and aging
Peptide aggregation was performed as previously described (44); brieﬂy, Aβ25–35
peptides (Sigma-Aldrich, USA) were dissolved in phosphate-buffered saline at a
concentration of 2 mg/ml and incubated for peptide aging or aggregation at 37 °C
for 4 days.
Surgical procedures
Unilateral infusion of Aβ25–35 (10 nmol/2 μl/rat) into the lateral ventricular region of brain
was used to produce a rat model of AD. For this purpose, rats were anesthetized with
injection of ketamine (90 mg/kg, i.p.) and xylazine (12 mg/kg, i.p.). Body temperature
was maintained at 36.5 ± 0.5 °C using a heating pad that was regulated by a rectal
temperature sensor. The rat head was ﬁxed in the stereotactic apparatus, and the skull was
exposed by making an incision in the midline scalp. The stereotaxic coordinates were
determined according to the rat brain atlas: anterior–posterior =−0.8 mm, medial–
lateral = ±1.6 mm, and dorsal–ventral = −4.2 mm (36). Aβ (10 nmol/rat) was injected
into the ventricle over 3 min using a 5-μl Hamilton microsyringe and infusion pump.
To avoid reﬂux, the rats were kept restrained, maintaining the injection needle in situ for
an additional 5 min after the infusion. After surgery, each rat was kept in a separate cage
for 24 h.
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Drug treatments
Drug and/or vehicle were delivered via intraperitoneal or intranasal route. Separate groups of
Aβ25–35-injected rats (15 rats/each group) received normal saline (NS) and/or insulin (Exir
Pharmaceuticals, Iran) (0.1, 0.2, and 0.3 IU) for 14 consecutive days following the surgery
procedure. Control group did not receive any treatment. Solutions were freshly prepared on
the day of experimentation by dissolving drugs in physiological saline (0.9% NaCl). All
administrations were done in a constant volume of 20 μl. For intranasal delivery, each rat was
restrained and held with its neck parallel to the ﬂoor while a volume of 20 μl (10 μl/each
nostril) of liquid was administered using pipettor (30).
Morris water maze (MWM) test
The MWM consisted of a black circular pool (diameter: 130 cm, height: 60 cm) ﬁlled
with clear water maintained at a temperature of 25 ± 1 °C. A platform (diameter: 10 cm)
was placed in the center of one quadrant of the pool. During the training, the platform
was constantly maintained 1 cm below the surface of the water. The maze was located in
a room with visual cues. The starting points were pseudo-randomized for each trial. Rats
were released to the pool facing toward the wall and were allowed to search for the
submerged platform for 60 s. If the rats could ﬁnd the platform within 60 s, they were
allowed to stay on the platform for 20 s; if they could not ﬁnd the platform, they were
directed to the platform and allowed to stay there for 20 s. The rats were subjected to four
trials with a 10-min interval between each two trials for 5 consecutive days. The training
ﬁnished when 5-day trials were completed. On the last day of the trial, the platform was
removed and the rats were subjected to probe trial in which they searched for platform for
60 s. Also, the visible platform version of the MWM (platform 1 cm above the water and
marked by a beacon) was used to assess the escape motivation or impairment of visual
and/or motor performance.
Data of the escape latency (in training days) and the time spent in the target
quadrant (in probe trial) were collected by the video tracking equipment and processed by
a computer.
Statistical analyses
Descriptive data were expressed as mean ± standard error of mean (SEM). Comparison of
different groups was carried out by a repeated measure or a one-way ANOVA followed by
the post hoc Tukey test. All analyses were performed using IBM SPSS Statistics software
(version 22 for Windows; SPSS Inc., Chicago, IL, USA). In all comparisons, p< 0.05 was
considered signiﬁcant.
Results
Visible platform phase of MWM
There was no signiﬁcant difference between the treatment groups in the distance traveled and
the mean swim speed (data not shown).
Effect of intraperitoneal insulin administration on working memory
The average escape latency in the hidden platform phase decreased within the training days.
Moreover, group effect was a signiﬁcant determinant of escape latency time. Two-way
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ANOVA revealed signiﬁcant effects of group [F(4, 225) = 148.69, p< 0.001], day
[F(4, 225) = 950.25, p< 0.001], and group–day interaction [F(16, 225)= 12.27, p< 0.001].
An i.c.v. injection of 10 nmol Aβ25–35 resulted in a signiﬁcant decline in spatial learning,
with longer latency in searching for the platform. Inter-group analysis showed that
Aβ increased escape latency compared with control group (p< 0.001) (Fig. 1).
Intraperitoneal administration of 0.1, 0.2, and 0.3 IU insulin did not improve the learning
behavior on training days and no signiﬁcant differences were found compared with the
NS-received AD rats (p> 0.05) (Fig. 1).
Effect of intraperitoneal insulin administration on reference memory
In various groups, the total swimming time in the target quadrant in the probe test was
signiﬁcantly different [F(4, 49)= 123.39, p< 0.001]. Post hoc analysis showed a signiﬁcant
effect of Aβ injection on the time spent in the target quadrant compared with the control group
(p< 0.001). However, none of 0.1, 0.2, and 0.3 IU intraperitoneal insulin had improving
effect on reference memory in AD rats (Fig. 2).
Effect of intranasal insulin administration on working memory
Groups and days in intranasal administration of insulin were similar to the intraperitoneal
administration of insulin. Two-way ANOVA revealed signiﬁcant effects of group
[F(4, 225)= 252.67, p< 0.001], day [F(4, 225)= 994.45, p< 0.001], and group–day inter-
action [F(16, 225) = 13.27, p< 0.001].
Aβ administration resulted in a signiﬁcant decline in spatial learning, with longer latency
in searching for the platform. Inter-group analysis showed that Aβ increased escape latency
compared with the control group (p< 0.001).
Fig. 1. Average escape latencies
during training days on the hidden
platform task in different
groups. Each dot represents the
mean ± SEM. (i.p., intraperitoneal)
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Intranasal administration of 0.1 IU insulin did not improve the learning behavior
and training days, and no signiﬁcant differences were found compared with the
NS-received Aβ group (p > 0.05). However, treatment with 0.2 and 0.3 IU intranasal
insulin improved the acquisition performance compared with the Aβ + NS group
(p < 0.001) (Fig. 3).
Fig. 2. Average time spent in target
quadrant in probe trials in different
intraperitoneal groups. Each bar
represents the mean ± SEM
Fig. 3. Average escape latencies
during training days on the hidden
platform task in different groups.
Each dot represents the mean ±
SEM. **p< 0.001 compared with
the Aβ+NS group. (Repeated
measure followed by one-way
ANOVA and inter-group analysis)
(i.n., intranasal)
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Effect of intranasal insulin administration on reference memory
In the probe trials, the percentages of total swimming time in the target quadrant were
signiﬁcantly different in various groups [F(4, 49)= 100.17, p< 0.001]. Post hoc analysis
showed that treatment with 0.2 or 0.3 IU intranasal insulin reversed the reference memory
impairments induced by Aβ25–35 (p< 0.001) (Fig. 4).
Discussion
Fast, acute, and non-invasive administration of the treatments is the best method of drug
delivery in patients with AD (28). On the other hand, restriction of the entry of therapeutics
into the CNS by BBB is one of the major reasons that causes treatment failure (38).
Intranasal delivery of the therapeutics is a useful strategy to treat variety of CNS diseases
such as AD by bypassing BBB (8). There is evidence that direct acute administration
of insulin into the CNS may improve cognitional performance in AD (35). Hence, this
study was designed to evaluate the effect of intranasal administration of insulin on
Aβ-received rat.
The MWM test is used in the study of the neurobiology and neuropharmacology of
spatial learning and memory, and it has an important role in the validation of rodent models
for neurocognitive disorders such as AD (6, 50). Therefore, in this study, we used the MWM
test for the validation of the effect of insulin therapy on AD rat models.
Intracerebroventricular administration of Aβ in rats is used as a good model for certain
aspects of AD, and many studies have used this model for AD modeling (34, 42). In this
study, intracerebroventricular administration of Aβ showed a signiﬁcant impairment in
learning and memory, which was in line with other studies (7, 47).
Resistance to insulin action within the CNS or diabetes mellitus type III is associated
with AD, depression, and other neurologic diseases (4). High concentrations of insulin
receptors have been reported in the cerebral cortex and hippocampus (52), so insulin could
have direct effects on activity and cognitive function in the CNS (22). It inﬂuences cognitive
Fig. 4. Average time spent in target
quadrant in probe trials in different
intranasal groups. Each bar
represents the mean ± SEM.
**p< 0.001 compared with the
NS-received Aβ rats. (One-way
ANOVA followed by the post hoc
Tukey test)
Intranasal insulin treatment improves memory in AD 349
Physiology International (Acta Physiologica Hungarica) 103, 2016
functions by modulating neurotransmitter release and synaptic plasticity (24). Also, it
modulates acetylcholine and norepinephrine levels in brain and inﬂuences cognitive function
(19, 26).
According to the study by Wang et al. (53), induction of diabetes in transgenic AD mice
promotes the processing of Aβ precursor protein and results in increased Aβ generation,
neuritic plaque formation, and spatial memory deﬁcits. On the other hand, an accumulating
body of evidence shows that Aβ binds to the insulin receptor and disrupts insulin signaling
and long-term potentiation induction (12, 15). Insulin also modulates glucose utilization in
the hippocampus and other brain regions and facilitates memory at optimal levels in normal
metabolism (31). In addition, insulin participates in learning and memory by regulating
different pathways, such as expression of insulin receptor, insulin receptor substrate,
phosphoinositide 3-kinase, and protein kinase B (33).
Peripheral administration of insulin did not improve the learning behavior and memory
index in doses that were used in this study. Freude et al. (21) demonstrated that reduced
insulin signaling increases tau hyperphosphorylation in CNS. In another study, Chen et al. (9)
showed that intranasal insulin prevents anesthesia-induced hyperphosphorylation of tau in
3xTg-AD mice. Also, in the study by Yang et al. (54), subcutaneous insulin delivery did not
reduce brain tau phosphorylation.
Radioactively labeled insulin studies conﬁrm that it crosses the BBB by a saturable
mechanism. Banks et al. (2, 3) demonstrated that insulin crosses the BBB by a saturable
transport system. These levels of insulin slightly affect Aβ level, but it does not improve the
learning behavior and memory index in rat model.
In this study, 0.1 IU intranasal insulin administration did not improve working and
reference memory, but 0.2 and 0.3 IU insulin signiﬁcantly facilitated process of working and
reference memory. According to Zhang et al. (55) in memory-deﬁcient mice, 1.75 IU/day of
intranasal insulin for 1 week was shown to prevent anesthesia -induced spatial learning and
memory loss.
Babri et al. (1) showed that intra-hippocampal injections of insulin enhance memory.
This supports that insulin plays an important role in memory formation.
The study of Amnon revealed that a signiﬁcant quantity of ﬂuorescently labeled insulin
can be effectively delivered to the brain by intranasal administration of formulated
microemulsion. The study suggests that intranasal delivery of low-dose insulin would be
a potential treatment in pathologic conditions, such as AD (5). The study of Subramanian
and John conﬁrmed that intranasal insulin administration signiﬁcantly reduced Aβ level in
rat brain (49). Also, Yang et al. (54) found that insulin treatment could reduce tau
hyperphosphorylation in AD rat brains. In addition, evidence shows that enhancing insulin
signaling in the brain is a useful therapeutic option to overcome the CNS insulin resistance
in AD (46).
Intranasal insulin delivery occurs through extracellular transport, olfactory, and trigem-
inal perivascular channels, as well as possibly via axonal transport pathways (29, 51). The
olfactory nerve has physiologic attributes that provide extracellular and intracellular path-
ways into the CNS and bypass the BBB (25). Therefore, intranasal administration technique
is a unique system of drug delivery to the CNS without signiﬁcant changes in plasma insulin
or glucose levels (27).
It can be concluded that enhancing brain insulin signaling improves memory and
learning processes in AD; however, further investigations are needed to clarify the exact
mechanisms by which intranasal insulin improves cognitive performance.
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